Shots:
Christmas is a time of giving so PharmaShots would like to give all its 12K+ cherished subscribers and readers a huge thanks for their continued support and partnership
We look forward to working with you all in the years to come. Now it is the time for us both to relax and celebrate. We…
Shots:
Thank you for believing in us. We promise to always provide our readers with the excellent service that they can utilize to support and grow their business
We would like to announce our bespoke service which is a dedicated customized news alert service for you and your team, specific to any therapy area and…
Active Ingredient: Nivolumab
Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial
Dosage Form: Injection
Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1)
First Approval: US (22 Dec 2014), EU (19 Jun 2015)
Revenue Analysis of Opdivo
BMS’ Opdivo gives tough competition to other drugs in the…
“Putting Ourselves to the Test: Achieving Equity to End HIV” -Theme of the year 2022
Introduction:
HIV/AIDS is one of the top 10 cause of mortality. It is a chronic, epidemic disease caused by human immunodeficiency virus (HIV), a virus that infect WBC’s CD4 T-cell of the immune system.
HIV, a type of retrovirus that isn't…
Shots:
Dr. Barbara Delage talked about the key findings from the new study on malnutrition-related deaths. She also spoke about the birth condition, Orofacial cleft
Dr. Nicholas Kassebaum spoke about how malnutrition-related deaths could be prevented in children living with a cleft
The study was conducted in collaboration with Smile Train and the Institute for…
The US FDA approved 1 NDAs and 6 BLA in November 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 73 novel products in 2022
In November 2022, the major highlights drugs were Imfinzi (durvalumab) + Imjudo (tremelimumab) approval for metastatic non-small cell lung cancer, Elahere for…
Shots:
Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC)
Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemab
The interview gives an understanding of Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
Shots:
Brian spoke about why Respira Technologies has been rebranded as Qnovia
Brian also talked about how Qnovia is working to advance its first inhalable prescription smoking cessation therapy and its applications
The interview summarizes how this rebranding will accelerate Qnovia’s technology and products from others in the biotechnology space
Smriti: Would you please start off…
Shots:
Volker spoke about the granting of marketing authorization by EC to treat adults with active lupus nephritis.The approval was based on the results of the P-III AURORA study
Volker also talked about the collaboration between Aurinia and Otsuka Pharmaceutical for the development and commercialization of LUPKYNIS
The interview gives an understanding of how Aurinia…
Shots:
Robert spoke about the publication of the new study in the Heart Rhythm Journal about the Micra AV leadless pacemaker and how it is an effective therapy for patients with atrioventricular (AV) block
Robert talked about the study design and the key findings from the study evaluating Medtronic’s Micra AV device
The interview gives an understanding…

